| 5.4 0.43 (8.65%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.57  |
1-year : | 7.67 |
| Resists | First : | 5.62 |
Second : | 6.57 |
| Pivot price | 4.51 |
|||
| Supports | First : | 4.14 |
Second : | 3.22 |
| MAs | MA(5) : | 4.89 |
MA(20) : | 4.36 |
| MA(100) : | 4.14  |
MA(250) : | 34.68 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 88.9 |
D(3) : | 85.9 |
| RSI | RSI(14): 79.6 |
|||
| 52-week | High : | 216.4 | Low : | 1.91 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PBM ] has closed It is unclear right now based on current values. 49.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 91 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.63 - 5.65 | 5.65 - 5.67 |
| Low: | 4.88 - 4.9 | 4.9 - 4.92 |
| Close: | 5.37 - 5.39 | 5.39 - 5.43 |
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Wed, 02 Sep 2026
PSYENCE BIOMEDICAL LTD. SEC Filing (Sep 2, 2026) - Stock Titan
Wed, 26 Aug 2026
Psyence BioMed (Nasdaq: PBM) holders may resell 1.15M shares - Stock Titan
Tue, 18 Aug 2026
Psyence Biomedical stock surges on Trump ibogaine announcement - Investing.com
Tue, 18 Aug 2026
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development - GlobeNewswire
Wed, 03 Jun 2026
Psyence Labs Discloses Investment in PSYENCE BIOMEDICAL LTD. with 30.05% Stake - tradingview.com
Tue, 26 May 2026
PBM - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 9.7 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 31 (K) |
| EPS | -12.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -31.4 % |
| Return on Equity (ttm) | -58.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.43 |
| PEG Ratio | 0 |
| Price to Book value | 0.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|